Format

Send to

Choose Destination
Saudi J Anaesth. 2019 Jul-Sep;13(3):231-236. doi: 10.4103/sja.SJA_817_18.

Extended release granisetron: Review of pharmacologic considerations and clinical role in the perioperative setting.

Author information

1
Beth Israel Deaconess Medical Center, Department of Anesthesia, Critical Care, and Pain Medicine, Harvard Medical School, Boston, MA, USA.
2
University of Pennsylvania, Philadelphia, PA, USA.
3
Valley Anesthesiology and Pain Consultants, Phoenix, AZ, USA.
4
University of Arizona College of Medicine-Phoenix, Department of Anesthesiology, Phoenix, AZ, USA.
5
Creighton University School of Medicine, Department of Anesthesiology, Omaha, NE, USA.
6
Brigham and Women's Hospital, Department of Anesthesiology, Perioperative, and Pain Medicine, Harvard Medical School, Boston, MA, USA.

Abstract

In this review, we evaluate recent literature on use of ER granisetron in clinical practice as compared with current antiemetics and describe its potential uses for perioperative PONV prophylaxis and treatment. Recent literature was evaluated on ER granisetron use compared with currently used antiemetic agents ondansetron, droperidol, metoclopramide, promethazine, and dexamethasone with a focus on procedural anti-emesis. Though promising great effect, application of extended release granisetron to clinical use may be limited by it's increased relative cost.

KEYWORDS:

5-HT3 antagonists; anti-emetics; pharmacotherapy; post-operative nausea and vomiting

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
Loading ...
Support Center